These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. Mystakidou K; Stathopoulou E; Parpa E; Kouloulias V; Kouskouni E; Vlahos L J Cancer Res Clin Oncol; 2008 Dec; 134(12):1303-10. PubMed ID: 18504612 [TBL] [Abstract][Full Text] [Related]
3. [Ibandronate: keep life in motion]. Longo F; Mansueto G Tumori; 2004; 90(2):9-16. PubMed ID: 15237599 [No Abstract] [Full Text] [Related]
4. [Progress and problems in oral bisphosphonate]. Takeuchi Y Clin Calcium; 2014 Jan; 24(1):27-33. PubMed ID: 24369277 [TBL] [Abstract][Full Text] [Related]
5. Aredia: the once-monthly infusion for the treatment of bone metastases. Lipton A Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852 [TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates and reduction of skeletal events in patients with bone metastatic breast cancer. Rizzoli R Ann Oncol; 2004 May; 15(5):700-1. PubMed ID: 15111335 [No Abstract] [Full Text] [Related]
7. Bisphosphonates for breast cancer: questions answered, questions remaining. Layman R; Olson K; Van Poznak C Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453 [TBL] [Abstract][Full Text] [Related]
8. Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update. Pecherstorfer M Expert Opin Pharmacother; 2008 Dec; 9(17):3111-9. PubMed ID: 19006482 [TBL] [Abstract][Full Text] [Related]
9. Anti-tumor potential of bisphosphonates. Green JR Med Klin (Munich); 2000 Oct; 95 Suppl 2():23-8. PubMed ID: 11089384 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease. Kanakis I; Kousidou OCh; Karamanos NK In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191 [TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Clézardin P; Ebetino FH; Fournier PG Cancer Res; 2005 Jun; 65(12):4971-4. PubMed ID: 15958534 [TBL] [Abstract][Full Text] [Related]
12. Dosing of zoledronic acid throughout the treatment continuum in breast cancer. Hadji P; Gnant M; Aapro M; Lipton A; Coleman R Crit Rev Oncol Hematol; 2011 Aug; 79(2):175-88. PubMed ID: 20846875 [TBL] [Abstract][Full Text] [Related]
13. [Bone metastases in breast carcinoma. Bisphosphonate protects from complications]. MMW Fortschr Med; 2004 Apr; 146(14):45. PubMed ID: 15344758 [No Abstract] [Full Text] [Related]
14. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Westermann AM Ann Oncol; 2005 Mar; 16(3):513; author reply 513. PubMed ID: 15668265 [No Abstract] [Full Text] [Related]
15. Is it feasible to adjust bisphosphonate dose according to bone mineral density value in postmenopausal breast cancer patients with bone metastases? Delibasi T; Akkus NI; Altundag O; Pinar T; Altundag K Med Hypotheses; 2006; 66(6):1254-5. PubMed ID: 16413688 [No Abstract] [Full Text] [Related]
17. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963 [TBL] [Abstract][Full Text] [Related]